Abstract
Recent studies have documented dramatic decreases in opportunistic infections, hospitalizations, and mortality among HIV-infected persons, owing primarily to the advent of highly active antiretroviral medications. Unfortunately, not all segments of the population living with HIV benefit equally from treatment. In San Francisco, only about 30% of the HIV-infected urban poor take combination highly active antiretroviral medications, as compared with 88% of HIV-infected gay men. Practitioners who care for the urban poor are reluctant to prescribe these medications, fearing inadequate or inconsistent adherence to the complicated medical regimen. Persons typically must take 2 to 15 pills at a time, 2 to 3 times a day. Some of the medications require refrigeration, which may not be available to the homeless poor. Most homeless persons do not have food available to them on a consistent schedule. Therefore, they may have difficulty adhering to instructions to take medications only on an empty stomach or with food. Lack of a safe place to store medications may be an issue for some. In addition, many urban poor live with drug, alcohol, or mental health problems, which can interfere with taking medications as prescribed. Inconsistent adherence to medication regimens has serious consequences. Patients do not benefit fully from treatments, and they will become resistant to the medications in their regimen as well as to other medications in the same classes as those in their regimen. Development of resistance has implications for the broader public health, because inadvertent transmission of multidrug-resistant strains of HIV has been demonstrated. Concern that the urban poor will not adhere to highly active antiretroviral medication regimens has led to debate on the role of clinicians and public health officials in determining who can comply with these regimens. Rather than define the characteristics that would predict adherence to these regimens, the San Francisco Department of Public Health created a program to support adherence among those who may have the greatest difficulty complying with complicated highly active antiretroviral medication regimens. The program, dubbed the Action Point Adherence Project, was conceived through a community planning process in preparation for a city-wide summit on HIV/AIDS that took place in January 1998. Action Point is funded by the city and the county of San Francisco. Now in its 10th month, the program continues to show promising evidence of improving clients' biological and social indicators.
Full Text
The Full Text of this article is available as a PDF (161.1 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Bangsberg D. R., Hecht F. M., Charlebois E. D., Zolopa A. R., Holodniy M., Sheiner L., Bamberger J. D., Chesney M. A., Moss A. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS. 2000 Mar 10;14(4):357–366. doi: 10.1097/00002030-200003100-00008. [DOI] [PubMed] [Google Scholar]
- Bangsberg D., Tulsky J. P., Hecht F. M., Moss A. R. Protease inhibitors in the homeless. JAMA. 1997 Jul 2;278(1):63–65. [PubMed] [Google Scholar]
- Hecht F. M., Grant R. M., Petropoulos C. J., Dillon B., Chesney M. A., Tian H., Hellmann N. S., Bandrapalli N. I., Digilio L., Branson B. Sexual transmission of an HIV-1 variant resistant to multiple reverse-transcriptase and protease inhibitors. N Engl J Med. 1998 Jul 30;339(5):307–311. doi: 10.1056/NEJM199807303390504. [DOI] [PubMed] [Google Scholar]
- Palella F. J., Jr, Delaney K. M., Moorman A. C., Loveless M. O., Fuhrer J., Satten G. A., Aschman D. J., Holmberg S. D. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998 Mar 26;338(13):853–860. doi: 10.1056/NEJM199803263381301. [DOI] [PubMed] [Google Scholar]
- Sendi P. P., Bucher H. C., Harr T., Craig B. A., Schwietert M., Pfluger D., Gafni A., Battegay M. Cost effectiveness of highly active antiretroviral therapy in HIV-infected patients. Swiss HIV Cohort Study. AIDS. 1999 Jun 18;13(9):1115–1122. doi: 10.1097/00002030-199906180-00016. [DOI] [PubMed] [Google Scholar]
- Staszewski S., DeMasi R., Hill A. M., Dawson D. HIV-1 RNA, CD4 cell count and the risk of progression to AIDS and death during treatment with HIV-1 reverse transcriptase inhibitors. AIDS. 1998 Oct 22;12(15):1991–1997. doi: 10.1097/00002030-199815000-00010. [DOI] [PubMed] [Google Scholar]
- Vittinghoff E., Scheer S., O'Malley P., Colfax G., Holmberg S. D., Buchbinder S. P. Combination antiretroviral therapy and recent declines in AIDS incidence and mortality. J Infect Dis. 1999 Mar;179(3):717–720. doi: 10.1086/314623. [DOI] [PubMed] [Google Scholar]
- Volberding P. A., Deeks S. G. Antiretroviral therapy for HIV infection: promises and problems. JAMA. 1998 May 6;279(17):1343–1344. doi: 10.1001/jama.279.17.1343. [DOI] [PubMed] [Google Scholar]